Venture Capital & Emerging Companies

Mintz advised Seven Starling, a virtual health provider specializing in mental health care during fertility, pregnancy, postpartum, and early parenthood, on its $8M Series A-Prime financing, led by Rethink Impact.

Mintz advised Charlesbank on its acquisition of Q6 Cyber to support growth through strategic expansion in cyber intelligence and fraud prevention.

Mintz represented S2G Investments in its $40 million Series B financing of Sojo Industries.

Mintz advised SYN Ventures, a leading venture capital firm focused on cybersecurity investments, in its $20 million Series A investment in SquareX, the pioneer in Browser Detection and Response.

Mintz advised Persivia, a leader in AI-driven digital health solutions, on its $107 million investment from Aldrich Capital Partners, a growth equity firm focused on high-potential healthcare and technology companies.

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

Mintz advised Lightkeeper, a provider of data, analytics, risk management, and reporting solutions for investment managers, in a growth investment from PSG, a growth equity firm focused on software- and technology-enabled services companies.

Mintz represented Granata Bio Corporation, a biopharma company focused on invigorating the $3.6 billion global infertility medication market, in its $15 million Series A+ funding round.

Mintz advised Relation Therapeutics, an industry leader in deploying computation and experimentation to drug discovery, on an equity investment of $15 million from GSK in connection with two simultaneous strategic collaborations with GSK, a global biopharma company. The collaborations are aimed at advancing the development of novel therapeutics for fibrotic diseases and osteoarthritis.

Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.

Members Dan DeWolf and Talia Primor of Mintz’s Venture Capital & Emerging Companies Practice advised SYN Ventures in the formation of its debut fund, focused on investing in cybersecurity innovators. 

Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.

Mintz advised Oberon Fuels, a developer of an ultra-low-carbon fuel known as renewable dimethyl ether (rDME), on a strategic collaboration with propane fuel distributor SHV Energy. The agreement will help Oberon scale up its pilot facility to produce the first rDME fuel in the United States.

Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.

Mintz represented Vida Ventures on the $600 million fundraise for its Vida II fund, which will be used to further the firm’s life sciences platform. Founded less than two years ago, Vida now has approximately $1 billion under management.

After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).

Mintz has represented oncology-focused biotherapeutic company Inhibrx LP since its inception. Mintz attorneys have advised Inhibrx on licensing deals and financing deals involving unusual corporate and tax structuring and international aspects.

Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.

Mintz has represented product coating and additive maker NBD Nano since 2013 on matters including financings led by Phoenix Venture Partners and BASF. Mintz also assists NBD with joint development agreements.